InsidersTradesSigma
리메드 Stock: price and directors' dealings · South Korea · DART (FSS)
Track the 리메드 share price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 리메드 has logged 76 insider filings. Market capitalisation: €80.5bn. The latest transaction was filed on 24 June 2026 (Other). Among the most active insiders: 이근용. Every trade is free.
76
Insider Decl.
n/a
Thresholds
n/a
8 ops.
Buy Volume
n/a
2 ops.
Sell Volume
13Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,061 of 28,134 companies
37.5
score / 100
Value29
Quality46
FCF yld1.7%
Earn yld0.6%
EV/EBITDA47.5x
ROE1.8%
Gross mgn57%
Net mgn2.1%
Debt/EBITDA2.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 24 June 2026
Declarations76 total
576,725 sharesKRXDART:20250903000264
25 of 76 declarations
About 리메드
리메드 operates in the healthcare and pharmaceutical sector, listed on the XKRX market. The company focuses on developing innovative solutions to enhance healthcare.